Clinical Trial

MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Luminal breast cancer is characterized by marked heterogeneity, resulting in diverse treatment responses and long-term outcomes. This project aims to integrate MRI and multiomics data to achieve non-invasive molecular typing and precise response prediction. By linking imaging phenotypes with underlying molecular and pathological characteristics, the investigators will develop predictive models for treatment resistance, recurrence, and metastasis, ultimately supporting personalized treatment strategies and precision oncology.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-07-02; most recent amendment 2026-07-18.
Trial Details
NCT Number NCT07692230
Lead Sponsor Fudan University
Conditions HR Positive/HER-2 Negative Breast Cancer
Enrollment 2,000 participants
Start Date 2026-01-06
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-21